FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.
Location: Switzerland
Employees: 11-50
Total raised: $62.11M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Omega Fund... | omegafunds... |
| - | Life Scien... | lspvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.12.2025 | Series A | $50M | M Ventures |
| 23.04.2020 | Seed | $12.11M | Omega Fund... |
Mentions in press and media 12
| Date | Title | Description |
| 24.12.2025 | FoRx Therapeutics: $50 Million Series A Raised To Advance FORX-428 | FoRx Therapeutics, a clinical-stage biotech developing precision oncology medicines, has closed an insider-led $50 million (CHF 40 million) Series A financing to advance its lead candidate, FORX-428, into and through Phase 1 clinical develo... |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 18.12.2025 | FoRx Therapeutics raises $50 million to advance clinical trials | Existing investors, including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) ... |
| 18.12.2025 | Swiss BioTech FoRx Therapeutics closes €42 million for next-generation DNA repair cancer therapy | Basel-based FoRx Therapeutics, a clinical-stage BioTech company developing precision anti-cancer therapeutics, today announced the close of an insider-led €42 million ($50 million) Series A financing. Existing investors including EQT Life S... |
| 11.08.2025 | Two biotech start-ups significantly closer to market | Results of the RAAINBOW Phase 2/3 trial showing efficacy and safety of Legacy Healthcare’s Cinainu in children and adolescents with moderate to severe alopecia areata (AA) have been published in the British Journal of Dermatology. AA is a ... |
| 22.04.2021 | Senior leadership appointments at fintech and pharma startups | |
| 22.04.2021 | Senior leadership appointments at fintech and pharma startups | Jörg Bode, a financial expert with recognised leadership skills and a long career at renowned investment banks, is the new CEO of the Zurich-based provider of creates off-balance sheet securitisation platforms GenTwo. He initially made his ... |
| 22.04.2020 | Basel-based FoRx Therapeutics secures EUR 10 million seed round | |
| 22.04.2020 | Basel-based FoRx Therapeutics secures EUR 10 million seed round | Established in October 2019 in Basel, FoRx is developing a new generation of drugs against a unique target class for the treatment of cancer. The company’s scientific foundations are built on the pioneering work of Professor Thanos Halazone... |
| 22.04.2020 | FoRx Therapeutics Closes €10M Seed Financing Round | FoRx Therapeutics, a Basel, Switzerland-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways, closed a EUR 10m seed financing round. The round was led by M Ventures ... |
Show more